MELK and kidney cancer: These findings suggest that dual blockade using a combination of a TOPK inhibitor (OTS514) and a MELK inhibitor (OTS167) at the lower dose may be a promising molecular-targeted therapy for kidney cancer patients with avoidance or reduction of their toxicity.